Philip J. Johnson

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi et al. · Journal of Clinical Oncology · 2014 · 2.8K citations · Full text

Medicine, Oncology, Clinical Epidemiology +16

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study

Joong‐Won Park, Minshan Chen, M. Colombo et al. · Liver International · 2015 · 1.3K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Meeting report: International autoimmune hepatitis group

Philip J. Johnson, Ian G. McFarlane · Hepatology · 1993 · 1.1K citations

Life Sciences, Immunology, Internal Medicine +12

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Philip J. Johnson, Shukui Qin, Joong‐Won Park et al. · Journal of Clinical Oncology · 2013 · 775 citations · Full text

Medicine, Oncology, Pharmacology +14

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda et al. · Gut · 2019 · 723 citations · Full text

Medicine, Oncology, Pharmacotherapy +17